Vincenzo Silani is Full Professor of Neurology and Chairman of the Department of Neurology-Stroke Unit and Laboratory of Neuroscience of the University of Milan Medical School at the IRCCS Istituto Auxologico Italiano and Director of “Dino Ferrari” Centre for Neuromuscular and Neurodegenerative Disease of the University of Milan Medical School.
Prof. Silani graduated in 1977 as M.D. at the University of Milan Medical School and he obtained the Specialties of both Neurology (1981) and Neurosurgery (1989). Post-doctoral Fellow in the Department of Neurology-Baylor College of Medicine in Houston (1979-81), Visiting Professor in Neurology at the Baylor College of Medicine (1999), he was CoChairman (2002-2005) and Chairman (2005-2007) of the European ALS Consortium (EALSC). Director European Neurological Society (ENS) – Subcommittee for Motor Neuron Disease (2008-2013), he is now Co-Director of the European Academy of Neurology (EAN) Subspeciality Panel ALS and Frontotemporal Dementia (2013-present). Author of more than 280 scientific publications (H-index 51, Scopus), he was invited lecturer in more than 200 international meetings
Prof. Silani developed an ALS Center in Milan with a large database of SALS/FALS biosamples. He founded also the SLAGEN Italian Consortium (2009) for genetic research aiming to define the genetic background both in FALS and SALS. He largely contributed to define the expression of several genes in Italy, investigating the functional role of TDP43, FUS/TLS, and C9ORF72. He acted as the PI of many clinical trials in ALS and have been the recipient of many national and international grants. More specifically, He has been awarded by the Italian AriSLA with the project EXOMEFALS and NOVALS, aiming at the identification of new genes in FALS using exon capture and short-read sequencing (Profilin1, TUBA4A, TBK1, CCNF, ANXA11, NEK1, and KIF5A). Stem cells have received a large interest along the years as demonstrated by many contributions. More recently, he has been interested in FTD and dementia beside extrapyramidal disorders, largely contributing also to these areas of research, considering the neurodegeneration as a biological continuum. He successfully administered projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project. His contribution has been well received in defining clinical guidelines related to neurodegenerative diseases both for patients and animal models. The most recent review in Lancet Neurology co-signed with Hiroshi Mitsumoto and Benjamin R. Brooks (Lancet Neurol 2014) testifies his commitment to find new therapeutical strategies in ALS as in other neurodegenerative disorders.